OCUL — OCULAR THERAPEUTIX, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1393434 ·
Last close
$8.29
Market Cap
$1.82B
52W High
$11.50
52W Low
$7.38
ADV30
2,891,361
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,785,000 | 9,456,000 | -93,340,000 | -88,612,000 | 732,529,000 | 666,699,000 | 150,955,000 |
| Dec 2025 | 13,250,000 | 11,656,000 | -69,760,000 | -64,654,000 | 808,057,000 | 737,060,000 | 153,747,000 |
| Sep 2025 | 14,544,000 | 12,770,000 | -68,698,000 | -69,418,000 | 410,882,000 | 344,772,000 | 152,653,000 |
| Jun 2025 | 13,459,000 | 11,515,000 | -67,641,000 | -67,814,000 | 451,333,000 | 391,134,000 | 145,417,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-204,883,000
Investing CF
$-11,880,000
Financing CF
$561,721,000
CapEx
$-12,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,157,023,000
Inventory
$3,564,000
Receivables
$30,650,000
ST Investments
—
EBIT TTM
$-254,105,000
Pretax Income TTM
$-265,939,000
Interest Exp TTM
$11,834,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$52,038,000
EBITDA
$-294,815,008
Free Cash Flow
$-148,761,504
Enterprise Value
$1,214,806,784
Total Cash
$666,699,008
Total Debt
$79,462,000
Shares Out
218,960,358
Trailing EPS
$-1.44
Book Value
$3.03
ROE
-68.6%
ROA
-32.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,951,000 | -270,017,000 | -265,939,000 | 808,057,000 | 153,747,000 | — | -204,883,000 |
| Dec 2024 | 63,723,000 | -171,781,000 | -193,506,000 | 457,935,000 | 142,591,000 | — | -134,677,000 |
| Dec 2023 | 58,443,000 | -82,382,000 | -80,736,000 | 252,060,000 | 160,929,000 | — | -70,234,000 |
| Dec 2022 | 51,494,000 | -78,654,000 | -71,038,000 | 149,289,000 | 113,910,000 | — | -59,603,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLPG | Lakefront Biotherapeutics NV | $1.81B | $27.49 | — |
| OCS | Oculis Holding AG | $1.81B | $29.93 | — |
| NRIX | Nurix Therapeutics, Inc. | $1.80B | $17.38 | — |
| GLPGF | Lakefront Biotherapeutics NV | $1.85B | $28.08 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.85B | $81.41 | — |
News headlines (Yahoo Finance, 1h cache)
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
2026-05-26 22:26 · Yahoo
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
2026-05-19 17:26 · Yahoo
3 Stocks Under $10 That Fall Short
2026-05-15 15:00 · Yahoo
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 11:00 · Yahoo
Ocular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation Diverge
2026-05-07 13:21 · Yahoo
Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile Returns
2026-05-06 12:15 · Yahoo
Ocular Therapeutix Q1 Earnings Call Highlights
2026-05-05 19:27 · Yahoo
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
2026-05-05 13:15 · Yahoo
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
2026-05-05 11:37 · Yahoo
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-05 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.